SUMMARY

• RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for subcutaneous (SC) administration is a coformulation of amivantamab with recombinant human hyaluronidase PH20 (rHuPH20).¹
• Of the 206 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with RYBREVANT FASPRO in combination with LAZCLUZE, 35% were aged ≥65 years and 9% were aged ≥75 years.²
• The safety of RYBREVANT FASPRO in combination with other antineoplastic drugs or as a single agent for its approved indications has been established in adequate and well-controlled studies of RYBREVANT intravenous (IV) in combination with other antineoplastic drugs and as a single agent.²
  • Of the 421 patients with locally advanced or metastatic NSCLC treated with RYBREVANT IV in combination with LAZCLUZE in the MARIPOSA study, 45% were aged ≥65 years and 12% were aged ≥75 years.
  • Of the 130 patients with locally advanced or metastatic NSCLC treated with RYBREVANT IV in combination with carboplatin and pemetrexed in the MARIPOSA-2 study, 40% were aged ≥65 years and 10% were aged ≥75 years.
  • Of the 151 patients with locally advanced or metastatic NSCLC treated with RYBREVANT IV in combination with carboplatin and pemetrexed in the PAPILLON study, 37% were aged ≥65 years and 8% were aged ≥75 years.
  • Of the 302 patients with locally advanced or metastatic NSCLC treated with RYBREVANT IV as a single agent in the CHRYSALIS study, 39% were aged ≥65 years and 11% were aged ≥75 years.
• No clinically important differences in safety or efficacy were observed between patients who were aged ≥65 years and younger patients.²
• Please refer to RYBREVANT FASPRO product labeling for additional information.²

PRODUCT LABELING

• RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT+Faspro-pi.pdf.
• RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.
• LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf.

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 08 December 2025.